Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside of the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing. The collaboration now spans four disease areas: neurodegeneration, oncology, autoimmunity and metabolic diseases.